ArticleCancer communications (London, England)2022

Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer.

Bo Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.